New tests for early detection of pancreatic cancer using imaging and blood samples
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
This study is looking for new ways to spot pancreatic cancer early by using blood tests and advanced MRI scans, making it easier and more comfortable for people at high risk to get checked out.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11076308 on NIH RePORTER |
What this research studies
This research aims to develop and validate innovative screening tools for the early detection of pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC). It focuses on using liquid biomarkers from blood samples combined with advanced imaging techniques, particularly magnetic resonance imaging (MRI), to identify high-risk individuals. The study emphasizes the importance of sensitivity, feasibility, and patient acceptability in its approach, ensuring that the tests are practical and comfortable for patients. If successful, these methods could lead to earlier diagnosis and better outcomes for those at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for pancreatic cancer, such as those with a family history of the disease or specific genetic predispositions.
Not a fit: Patients who do not have risk factors for pancreatic cancer or those with advanced-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of pancreatic cancer, improving treatment options and survival rates for patients.
How similar studies have performed: Previous research has shown promise in using similar biomarker and imaging approaches for early cancer detection, indicating potential for success in this novel application.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Sears, Rosalie C — Oregon Health & Science University
- Study coordinator: Sears, Rosalie C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.